Regenerative medicine leader **Mesoblast Limited** has officially announced the successful completion of patient enrollment for its pivotal **Phase 3 clinical trial** evaluating **rexlemestrocel-L**. The study, which includes 300 patients, aims to determine the efficacy of this **allogeneic mesenchymal precursor cell (MPC)** therapy in treating chronic low back pain caused by degenerative disc disease.
The trial is specifically designed to assess whether a single intra-disc injection of **rexlemestrocel-L** can provide long-term pain relief and improved functional outcomes for patients who have failed to respond to conventional **conservative treatments**. By utilizing highly potent **mesenchymal precursor cells**, the therapy targets the underlying inflammation associated with discogenic pain, rather than merely masking symptoms.
The recruitment of 300 participants marks a significant milestone in the development of this **cell-based therapeutic**. Clinical investigators will now monitor these subjects to gather primary and secondary endpoint data, which will be essential for potential **U.S. Food and Drug Administration (FDA)** approval. The trial focuses on patients suffering from moderate to severe chronic back pain, a condition that currently carries a massive global disease burden.
Current standard-of-care options for chronic discogenic back pain are often limited to physical therapy, analgesic medication, or invasive spinal fusion surgery. If proven effective in this final stage of testing, **rexlemestrocel-L** could offer a non-surgical alternative, potentially reducing the reliance on **opioid-based painkillers** and avoiding the risks associated with major orthopedic procedures.
**Mesoblast** has indicated that the data from this trial will be critical in shaping the regulatory pathway for **rexlemestrocel-L**. The company’s proprietary **MPC technology** has previously shown promise in early-stage trials by stabilizing the disc environment and promoting a favorable biological response.
Medical professionals and industry observers are keenly awaiting the 12-month follow-up data, which is expected to provide definitive evidence regarding the therapy’s ability to offer sustained pain reduction. With enrollment finalized, the focus shifts to the rigorous data analysis phase, a necessary precursor for any potential **Biologics License Application (BLA)**. As the company moves toward the study’s conclusion, this trial stands as a significant test for the viability of **regenerative medicine** in the orthopedics sector.
